Juniper Pharmaceuticals is developing therapeutics that address unmet medical needs in women’s health. Our current pipeline leverages the 505(b)(2) regulatory pathway with new formulations of existing pharmaceuticals.
Founded in 1986 as Columbia Laboratories, Inc., the Company has a successful history in developing pharmaceutical products, including CRINONE® 8% (progesterone gel), which is marketed by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide and by Allergan, Inc. in the U.S..
We are currently developing COL-1077, a 10% lidocaine bioadhesive gel intended as an acute use anesthetic for minimally invasive gynecologic procedures, and three candidates using our segmented intravaginal ring (IVR) technology.
We are leveraging in-house pharmaceutical development, clinical trial supply manufacturing, and analytical capabilities to advance an internal product pipeline, while also providing valuable intellectual property-related consultative services to our pharmaceutical industry customers.
Juniper is positioned for success with a highly experienced leadership team in combination with a strong balance sheet and positive cash flows to fund a proprietary pipeline for long term value creation.
We have a growing revenue stream, our next product candidate in is Phase 2 development, and we are building our pharmaceutical product pipeline, using our novel drug delivery technologies to develop women’s health products that address unmet medical needs.
We are looking for people who are driven to tackle challenges that are geared towards developing and improving therapeutic options for women. If you enjoy working in a collaborative environment as a valued team member, and are passionate about our vision, we’d like to hear from you.
8 Orchard Place
Nottingham Business Park
Phone: 0115 871 8865
Website: Juniper Pharma Services